sorafenib + pazopanib

Sorafenib + pazopanib is a combination of two small molecule multi-kinase inhibitors, both of which target multiple receptor tyrosine kinases involved in tumor growth and angiogenesis. Sorafenib inhibits vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3), platelet-derived growth factor receptor beta (PDGFRB), RAF kinases (including BRAF and CRAF), FLT3, c-KIT, and RET. Pazopanib targets VEGFR-1/2/3 with high affinity and also inhibits PDGFRA/B, FGFR1/2, and c-KIT. Both drugs are approved individually for the treatment of advanced renal cell carcinoma (RCC) and soft tissue sarcoma; they have also been studied in desmoid tumors and other malignancies as monotherapies. There is no evidence that the fixed combination "sorafenib + pazopanib" is an approved or widely used clinical regimen; rather, these agents are typically used sequentially or compared head-to-head in clinical trials[1][7][9]. Their mechanisms overlap but their toxicity profiles differ.

Brand names

VotrientNexavar

Other names

pazopanib and sorafenib sequenceSWITCH-II trial regimen